Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: A mechanism sensitive to the kunitz protease inhibitor

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Costa, Rita ^a   Ferreira da Silva, Frederico ^a   Saraiva, Maria J ^a,b   Cardoso, Isabel ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; ISOPROTEIN; PREALBUMIN; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; APROTININ; THIAZOLE DERIVATIVE; THIOFLAVINE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; HUMAN; MASS SPECTROMETRY; MOLECULAR MECHANICS; NEUROPROTECTION; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVERSED PHASE LIQUID CHROMATOGRAPHY; SEQUENCE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; DRUG EFFECT; ELECTRON MICROSCOPY; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APROTININ; HUMANS; MICROSCOPY, ELECTRON; PREALBUMIN; RECOMBINANT PROTEINS; THIAZOLES;

EID: 51449096179     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002899     Document Type: Article

References (44)

1. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101: 1172-84.
2. Bellucci C, Lilli C, Baroni T, Parnetti L, Sorbi S, et al. (2007) Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease. Mol Med 13: 542-50.
3. Vetrivel KS, Zhang X, Meckler X, Cheng H, Lee S, et al. (2008) Evidence that CD147 modulation of Abeta levels is mediated by extracellular degradation of secreted Abeta. J Biol Chem. (in press).
4. Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J Biol Chem 276: 24540-8.
5. Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, et al. (2005) Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281: 30471-8.
6. Nazer B, Hong S, Selkoe DJ (2008) LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol Dis 30: 94-102.
7. Malito E, Hulse RE, Tang WJ (2008) Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci. (in press).
8. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci 91: 8368-8372.
9. Chauhan VP, Ray I, Chauhan A, Wisniewski HM (1999) Binding of gelsolin, a secretory protein, to amyloid beta-protein. Biochem Biophys Res Commun 258: 241-6.
10. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8: 1390-7.
11. Stein TD, Johnson JA (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 22: 7380-8.
12. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, et al. (2004) Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 24: 7707-17.
13. Choi SH, Leight SN, Lee VM, Li T, Wong PC, et al. (2007) Accelerated A-Beta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 27: 7006-10.
14. Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS (1985) Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem 260: 11793-8.
15. Woeber KA, Ingbar SH (1968) The contribution of thyroxine-binding prealbumin to the binding of thyroxine in human serum, as assessed by immunoadsorption. J Clin Invest 47: 1710-21.
16. Liz MA, Faro CJ, Saraiva MJ, Sousa MM (2004) Transthyretin, a new cryptic protease. J Biol Chem 279: 21431-8.
17. Liz MA, Gomes CM, Saraiva MJ, Sousa MM (2007) ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J Lipid Res 48: 2385-95.
18. Schwarzman AL, Goldgaber D (1996) Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. Ciba Found Symp 199: 146-60.
19. Costa R, Gonçalves A, Saraiva MJ, Cardoso I (2008) Transthyretin binding to A-Beta peptide-impact on A-Beta fibrillogenesis and toxicity. FEBS Lett 582: 936-42.
20. Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A 92: 9368-72.
21. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, et al. (2007) Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A 105: 2681-6.
22. Palha JA, Moreira P, Wisniewski T, Frangione B, Saraiva MJ (1996) Transthyretin gene in Alzheimer's disease patients. Neurosci Lett 204: 212-4.
23. Vardy ER, Catto AJ, Hooper NM (2005) Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med 11: 464-72.
24. Wang YJ, Zhou HD, Zhou XF (2006) Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 11: 931-8.
25. Wang DS, Dickson DW, Malter JS (2006) beta-Amyloid Degradation and Alzheimer's Disease. J Biomed Biotechnol 2006: 58406.
26. Furuya H, Saraiva MJ, Gawinowicz MA, Alves IL, Costa PP, et al. (1991) Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP). Biochemistry 30: 2415-21.
27. Almeida MR, Damas AM, Lans MC, Brouwer A, Saraiva MJ (1997) Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine 6: 309-15.
28. Lowry OH, Rosenbrough NJ, Farr AL, Randall J (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
29. Moir RD, Tanzi RE (2005) LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP. Curr Alzheimer Res 2: 269-73.
30. Serot JM, Christmann D, Dubost T, Couturier M (1997) Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 63: 506-8.
31. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 28: 155-63.
32. Teplow DB (1998) Structural and kinetic features of amyloid beta-protein fibrillogenesis. Amyloid 5: 121-42.
33. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: A23-31.
34. Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, et al. (1999) A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 399: 776-81.
35. Lansbury PT Jr, Kosik KS (2000) Neurodegeneration: new clues on inclusions. Chem Biol 7: R9-R12.
36. Haggqvist B, Naslund J, Sletten K, Westermark GT, Mucchiano G, et al. (1999) Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc Natl Acad Sci U S A 96: 8669-74.
37. Cerini C, Geider S, Dussol B, Hennequin C, Daudon M, et al. (1999) Nucleation of calcium oxalate crystals by albumin: involvement in the prevention of stone formation. Kidney Int 55: 1776-86.
38. Rago JV, Vath GM, Tripp TJ, Bohach GA, Ohlendorf DH, et al. (2000) Staphylococcal exfoliative toxins cleave alpha- and beta-melanocyte-stimulating hormones. Infect Immun 68: 2366-8.
39. Sparks DL (2007) Cholesterol metabolism and brain amyloidosis: evidence for a role of copper in the clearance of Abeta through the liver. Curr Alzheimer Res 4: 165-9.
40. Shirahama T, Skinner M, Westermark P, Rubinow A, Cohen AS, et al. (1982) Senile cerebral amyloid. Prealbumin as a common constituent in the neuritic plaque, in the neurofibrillary tangle, and in the microangiopathic lesion. Am J Pathol 107: 41-50.
41. Menendez-Gonzalez M, Perez-Pinera P, Martinez-Rivera M, Calatayud MT, Blazquez Menes B (2005) APP processing and the APP-KPI domain involvement in the amyloid cascade. Neurodegener Dis 2: 277-83.
42. Rohan de Silva HA, Jen A, Wickenden C, Jen LS, Wilkinson SL, et al. (1997) Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes. Brain Res Mol Brain Res 47: 147-56.
43. Caswell MD, Mok SS, Henry A, Cappai R, Klug G, et al. (1999) The amyloid beta-protein precursor of Alzheimer's disease is degraded extracellularly by a Kunitz protease inhibitor domain-sensitive trypsin-like serine protease in cultures of chick sympathetic neurons. Eur J Biochem 266: 509-16.
44. Ho L, Fukuchi K, Younkin SG (1996) The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. J Biol Chem 271: 30929-34.